Dabigatran is not a complete cure, but can only play a palliative effect, there is no cure rate. Dabidol, also known as Dupliyuzumab injection, is currently available for the treatment of severe and moderate atopic dermatitis targeted biological agents, which can selectively act on the interleukin 4 and 13 signaling pathway, rapid and effective improvement of itching, skin lesions in patients with atopic dermatitis, but it is difficult to achieve a complete cure. Clinical use of this drug after half a month, itching can be improved by about 24%, within a month to reach 50%; and skin lesions can be improved by 61% in two months, within 16 weeks to improve 77% and maintained in a stable state, effectively improve the quality of life of patients, but there are individual differences, the specific effect, the onset of the time to analyze the individual situation.